Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) using pre-steady-state kinetics

Antiviral Research

Volumn 106, Issue 1, 2014, Pages 1-4

  Muftuoglu, Yagmur ^a   Sohl, Christal D ^a   Mislak, Andrea C ^a   Mitsuya, Hiroaki ^b,c   Sarafianos, Stefan G ^d   Anderson, Karen S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KUMAMOTO UNIVERSITY   (Japan)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d University of Missouri   (United States)

Author keywords

EFdA; Enzyme kinetics; HIV; Polymerase; Reverse transcriptase

Indexed keywords

4' ETHYNYL 2 FLUORO 2' DEOXYADENOSINE; DEOXYADENOSINE TRIPHOSPHATE; DEOXYCYTIDINE TRIPHOSPHATE; ENTECAVIR; KP 1212; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; CARBOVIR; 4'-ETHYNYL-2-FLUORO-2'-DEOXYADENOSINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYADENOSINE DERIVATIVE; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; BINDING AFFINITY; BINDING SITE; CONCENTRATION RESPONSE; DNA STRAND; DRUG CONFORMATION; HUMAN IMMUNODEFICIENCY VIRUS 1; POLYMERIZATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; KINETICS;

ANTI-HIV AGENTS; DEOXYADENOSINES; HIV REVERSE TRANSCRIPTASE; HIV-1; KINETICS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84898717424     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.03.001     Document Type: Article

References (24)

1. N. Apostolova, A. Blas-Garcia, and J.V. Esplugues Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-gamma inhibition Trends Pharmacol. Sci. 32 2011 715 725
2. R.A. Domaoal, M. McMahon, C.L. Thio, C.M. Bailey, J. Tirado-Rives, A. Obikhod, M. Detorio, K.L. Rapp, R.F. Siliciano, R.F. Schinazi, and K.S. Anderson Pre-steady-state kinetic studies establish entecavir 5′-triphosphate as a substrate for HIV-1 reverse transcriptase J. Biol. Chem. 283 2008 5452 5459
3. J.Y. Feng, and K.S. Anderson Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase Biochemistry 38 1999 55 63 (Pubitemid 29035670)
4. K.S. Harris, W. Brabant, S. Styrchak, A. Gall, and R. Daifuku KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis Antiviral Res. 67 2005 1 9 (Pubitemid 40798912)
5. P. Iyidogan, and K.S. Anderson Understanding the molecular mechanism of sequence dependent tenofovir removal by HIV-1 reverse transcriptase: differences in primer binding site versus polypurine tract Antiviral Res. 95 2012 93 103
6. A.A. Johnson, A.S. Ray, J. Hanes, Z. Suo, J.M. Colacino, K.S. Anderson, and K.A. Johnson Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase J. Biol. Chem. 276 2001 40847 40857 (Pubitemid 37373231)
7. M.W. Kellinger, and K.A. Johnson Role of induced fit in limiting discrimination against AZT by HIV reverse transcriptase Biochemistry 50 2011 5008 5015
8. S.G. Kerr, and K.S. Anderson RNA dependent DNA replication fidelity of HIV-1 reverse transcriptase: evidence of discrimination between DNA and RNA substrates Biochemistry 36 1997 14056 14063 (Pubitemid 27509840)
9. J. Kim, A. Roberts, H. Yuan, Y. Xiong, and K.S. Anderson Nucleocapsid protein annealing of a primer-template enhances (+)-strand DNA synthesis and fidelity by HIV-1 reverse transcriptase J. Mol. Biol. 415 2012 866 880
10. K.A. Kirby, E. Michailidis, T.L. Fetterly, M.A. Steinbach, K. Singh, B. Marchand, M.D. Leslie, A.N. Hagedorn, E.N. Kodama, V.E. Marquez, S.H. Hughes, H. Mitsuya, M.A. Parniak, and S.G. Sarafianos Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine Antimicrob. Agents Chemother. 57 2013 6254 6264
11. K.A. Kirby, K. Singh, E. Michailidis, B. Marchand, E.N. Kodama, N. Ashida, H. Mitsuya, M.A. Parniak, and S.G. Sarafianos The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase Cell. Mol. Biol. (Noisy-le-Grand) 57 2011 40 46
12. E. Michailidis, B. Marchand, E.N. Kodama, K. Singh, M. Matsuoka, K.A. Kirby, E.M. Ryan, A.M. Sawani, E. Nagy, N. Ashida, H. Mitsuya, M.A. Parniak, and S.G. Sarafianos Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor J. Biol. Chem. 284 2009 35681 35691
13. E. Michailidis, E.M. Ryan, A. Hachiya, K.A. Kirby, B. Marchand, M.D. Leslie, A.D. Huber, Y.T. Ong, J.C. Jackson, K. Singh, E.N. Kodama, H. Mitsuya, M.A. Parniak, and S.G. Sarafianos Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA Retrovirology 10 2013 65
14. J.I. Mullins, L. Heath, J.P. Hughes, J. Kicha, S. Styrchak, K.G. Wong, U. Rao, A. Hansen, K.S. Harris, J.P. Laurent, D. Li, J.H. Simpson, J.M. Essigmann, L.A. Loeb, and J. Parkins Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461 PLoS One 14 2011 e15135
15. E. Murakami, A. Basavapathruni, W.D. Bradley, and K.S. Anderson Mechanism of action of a novel viral mutagenic covert nucleotide: molecular interactions with HIV-1 reverse transcriptase and host cell DNA polymerases Antiviral Res. 67 2005 10 17 (Pubitemid 40798913)
16. H. Nakata, M. Amano, Y. Koh, E. Kodama, G. Yang, C.M. Bailey, S. Kohgo, H. Hayakawa, M. Matsuoka, K.S. Anderson, Y.C. Cheng, and H. Mitsuya Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine Antimicrob. Agents Chemother. 51 2007 2701 2708 (Pubitemid 47206202)
17. H. Ohrui, S. Kohgo, H. Hayakawa, E. Kodama, M. Matsuoka, T. Nakata, and H. Mitsuya 2'-Deoxy-4'-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against wide spectrum of HIV-1 strains, favorable toxic profiles, and stability in plasma Nucleosides Nucleotides Nucleic Acids 26 2007 1543 1546 (Pubitemid 350240765)
18. A.S. Ray, A. Basavapathruni, and K.S. Anderson Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir J. Biol. Chem. 277 2002 40479 40490 (Pubitemid 35215625)
19. C.D. Sohl, R. Kasiviswanathan, J. Kim, U. Pradere, R.F. Schinazi, W.C. Copeland, H. Mitsuya, M. Baba, and K.S. Anderson Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase Mol. Pharmacol. 82 2012 125 133
20. C.D. Sohl, K. Singh, R. Kasiviswanathan, W.C. Copeland, H. Mitsuya, S.G. Sarafianos, and K.S. Anderson Mechanism of interaction of human mitochondrial DNA polymerase gamma with the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine indicates a low potential for host toxicity Antimicrob. Agents Chemother. 56 2012 1630 1634
21. C.D. Sohl, R. Kasiviswanathan, W.C. Copeland, and K.S. Anderson Mutations in human DNA polymerase gamma confer unique mechanisms of catalytic deficiency that mirror the disease severity in mitochondrial disorder patients Hum. Mol. Genet. 22 2013 1074 1085
22. E.P. Tchesnokov, A. Obikhod, R.F. Schinazi, and M. Gotte Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase J. Biol. Chem. 283 2008 34218 34228
23. J.A. Vaccaro, K.M. Parnell, S.A. Terezakis, and K.S. Anderson Mechanism of inhibition of the human immunodeficiency virus type 1 reverse transcriptase by d4TTP: an equivalent incorporation efficiency relative to the natural substrate dTTP Antimicrob. Agents Chemother. 44 2000 217 221 (Pubitemid 30010704)
24. W. Zhang, M.A. Parniak, H. Mitsuya, S.G. Sarafianos, P.W. Graebing, and L.C. Rohan Preformulation studies of EFdA, a novel nucleoside reverse transcriptase inhibitor for HIV prevention Drug Dev. Ind. Pharm. 2013 10.3109/03639045.2013.809535